JJ
CTNM

Johnson & Johnson’s Contineum Therapeutics CTNM Stock Holding History

Johnson & Johnson’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.4M Hold
1,979,173
– – 4.06% 5
2026
Q1 		$25.8M Hold
1,979,173
– – 3.96% 6
2025
Q4 		$22.6M Hold
1,979,173
– – 4.08% 6
2025
Q3 		$23.3M Hold
1,979,173
– – 4.61% 7
2025
Q2 		$8.13M Hold
1,979,173
– – 2.43% 8
2025
Q1 		$13.8M Hold
1,979,173
– – 4.04% 8
2024
Q4 		$29M Hold
1,979,173
– – 7.51% 5
2024
Q3 		$37.9M Hold
1,979,173
– – 8.86% 4
2024
Q2 		$34.9M Buy
+1,979,173
New +$31.9M 8.7% 5

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Johnson & Johnson's CTNM Position: Q2 2026 in Review

Johnson & Johnson held its Contineum Therapeutics (CTNM) position steady in Q2 2026 at 1,979,173 shares worth $32.4M. The position accounts for 4.06% of the portfolio, ranked #5.

Johnson & Johnson first reported a position in CTNM in Q2 2024 and has held it in 9 quarters since. The position peaked at $37.9M in Q3 2024. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Johnson & Johnson held 1,979,173 shares of Contineum Therapeutics worth $32.4M as of Q2 2026.
  • Johnson & Johnson left its Contineum Therapeutics share count unchanged in Q2 2026.
  • Contineum Therapeutics made up 4.06% of Johnson & Johnson's portfolio in Q2 2026, its #5 holding.
  • Johnson & Johnson first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Johnson & Johnson's Contineum Therapeutics position peaked at $37.9M in Q3 2024.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Johnson & Johnson's 13F filing for Q2 2026, filed 6 Aug 2026.